Australian Women Considering Yaz Class Action Lawsuit

yaz_lawsuit_bayer_multidistrict_litigation_yaz_settlements_yaz_yasmin_lawsuit_settlementsHundreds of women in Australia are considering filing a class action lawsuit targeted at Bayer, the pharmaceutical company behind the contraceptive pills Yaz and Yasmin. The latest reports estimate that the class action lawsuit could involve 600 women.

As cited in the article from Australia’s 7 News, the British Medical Journal published studies, including one from 2011, whose data demonstrated a three fold increased risk of blood clots in women using Yaz, Yasmin, and Ocella, the generic equivalent of Yaz, in comparison to those women using other kinds of contraceptive drugs.

Many of the women who are considering filing a Yaz lawsuit against Bayer have experienced serious side effects, some of which became so serious, hospitalization was necessary. One such victim, an Australian woman interviewed for the 7 News article, experienced a stroke that she believes is the result of having used Yaz.

The woman is considering legal action for the purposes of discontinuing the manufacture of drugs like Yaz, Yasmin, and Ocella. An additional motivating factor is to prevent other women from experiencing a Yaz related stroke.

The St. Louis class action attorneys at Carey Danis & Lowe represent individuals in lawsuits filed across the United States who have been negatively affected by defective drugs. We work diligently for our clients to win them the day in court they they so rightfully deserve. Contact our experienced trial lawyers today to explore your legal options and compensation eligibility if you believe that you have sustained a serious injury as the result of using either Yaz, Yasmin, or Ocella.

Carey Danis & Lowe is ready to work with you. Share your Yaz, Yasmin, or Ocella story with us today. Contact Carey Danis & Lowe by phone at 800.721.2519, or complete a confidential personal injury claim form.

References: Pharmaceutical litigation, Yaz/Yasmin
Tags: , , , , , , , , , , , , , ,